iTeos Therapeutics (ITOS) said Monday that it has agreed to be acquired by Concentra Biosciences for $10.047 per share in cash and a contingent value right.
The iTeos board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all iTeos stockholders, it said.
Concentra will commence a tender offer by Aug. 1 to acquire all iTeos' outstanding shares, and the deal is expected to close by Q3, the company said.
The offer will close only if a majority of iTeos shares are tendered, including those already held by Concentra and its affiliates, at least $475 million in cash is available at closing, and other standard conditions are met, iTeos said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。